Real experience of prophylaxis with emicizumab in patients with congenital haemophilia A with and without FVIII inhibitors in the HCUVA

被引：0
|
作者：
Heredia Cano, Angela [1 ]
Garcia Candel, Faustino [1 ]
Sanchez Villalobos, Maria [1 ]
Poveda Garcia, Andrea [1 ]
Torchia Esteban, Marcos [1 ]
Ruiz Ruiz, Estela [1 ]
Sanchez Salas, Jose Antonio [1 ]
Navarro Almenzar, Begona [1 ]
Caracena Lopez, Sara [2 ]
Perez Laencina, Marta [1 ]
Blazquez Soto, Juan Antonio [1 ]
机构：
[1] Hosp Clin Univ Virgen de la Arrixaca, Murcia, Spain
[2] Hosp Gen Univ Morales Meseguer, Murcia, Spain
来源：
HAEMOPHILIA | 2024年 / 30卷
关键词：
congenital haemophilia A; emicizumab; real experience;
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
PP-022 (1
引用
收藏
页码：31 / 32
页数：2
相关论文
共 50 条
  • [41] COST-EFFECTIVENESS OF EMICIZUMAB PROPHYLAXIS IN PATIENTS WITH HEMOPHILIA A WITHOUT INHIBITORS
    Olasupo, O.
    Matino, D.
    Iorio, A.
    Blackhouse, G.
    Xie, F.
    Tarride, J. E.
    VALUE IN HEALTH, 2022, 25 (07) : S428 - S428
  • [42] Emicizumab prophylaxis in infants with severe haemophilia A without inhibitors: Illustrative real-world cases to support shared decision-making
    Mason, Jane A.
    Young, Guy
    HAEMOPHILIA, 2021, 27 (05) : 724 - 729
  • [43] Measurement of recombinant porcine factor VIII in patients with congenital haemophilia A and inhibitors in the presence of emicizumab
    Pfrepper, Christian
    Klamroth, Robert
    Ettingshausen, Carmen Escuriola
    Petros, Sirak
    Siegemund, Annelie
    Siegemund, Thomas
    HAEMOPHILIA, 2024, 30 (02) : 545 - 553
  • [44] DETERMINING THE VALUE OF EMICIZUMAB FOR THE PROPHYLAXIS OF SEVERE HAEMOPHILIA A PATIENTS WITHOUT INHIBITORS IN SPAIN BY MULTI-CRITERIA DECISION ANALYSIS (MCDA)
    Alvarez, E.
    Alvarez, M. T.
    Cuervo-Arango, I
    Nunez, R.
    Perez-Santamarina, R.
    Poveda, J. L.
    Romero, J. A.
    Queralt, M.
    Pablo, Q.
    Luis, V
    Tort, M.
    Badia, F. J.
    VALUE IN HEALTH, 2019, 22 : S860 - S860
  • [45] COST-EFFECTIVENESS OF EMICIZUMAB VERSUS BY-PASSING AGENTS IN PATIENTS WITH HAEMOPHILIA A AND FVIII INHIBITORS IN FRANCE.
    Godard, C.
    Polack, B.
    Trossaert, M.
    Baffert, S.
    VALUE IN HEALTH, 2019, 22 : S846 - S846
  • [46] Real-world data of prophylaxis with emicizumab in children and adolescents with severe haemophilia: A single centre experience
    Michalopoulou, A.
    Dettoraki, A.
    Karelioti, H.
    Thymianou, S.
    Papageorgiou, N.
    Stamati, I.
    Saslis, S.
    Kapsimali, Z.
    Pergantou, H.
    HAEMOPHILIA, 2024, 30 : 61 - 61
  • [47] Efficacy, safety and cost of emicizumab prophylaxis in haemophilia A patients with inhibitors: A nationwide observational study in Taiwan
    Shen, Ming-Ching
    Chou, Sheng-Chieh
    Chiou, Shyh-Shin
    Lin, Pei-Chin
    Chen, Yeu-Chin
    Lin, Hsuan-Yu
    Lee, Yang-Cheng
    Huang, Cih-En
    Weng, Te-Fu
    Huang, Ting-Huan
    Chung, Chih-Yuan
    Chen, Jiann-Shiuh
    Chen, Shu-Huey
    Cheng, Shin-Nan
    Hsiao, Chih-Cheng
    Huang, Yen-Min
    Chen, Shih-Hsiang
    Yu, Yuan-Bin
    Lin, Shih-Chiang
    Lin, Ching-Yeh
    Peng, Ching-Tien
    Wang, Jiaan-Der
    HAEMOPHILIA, 2023, 29 (06) : 1499 - 1508
  • [48] Cost-utility analysis of emicizumab prophylaxis in haemophilia A patients with factor VIII inhibitors in Korea
    Lee, Hankil
    Cho, Hyeonseok
    Han, Jung Woo
    Kim, Ah-Young
    Park, Seonyoung
    Lee, Minjun
    Cho, Sunghwa
    Baik, Deborah
    Kang, Hye-Young
    HAEMOPHILIA, 2021, 27 (01) : E12 - E21
  • [49] Inhibitors and prophylaxis in paediatric haemophilia patients: Focus on the German experience
    Kurnik, Karin
    Auerswald, Guenter
    Kreuz, Wolfhart
    THROMBOSIS RESEARCH, 2014, 134 : S27 - S32
  • [50] ECONOMIC IMPACT OF EMICIZUMAB PROPHYLAXIS FOR HEMOPHILIA A WITH AND WITHOUT INHIBITORS
    Cortesi, P. A.
    Castaman, G.
    Mantovani, L. G.
    VALUE IN HEALTH, 2020, 23 : S699 - S699
12345